Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. reports clinical and corporate developments for its T cell receptor-engineered T cell therapy pipeline. The company’s cancer programs include TSC-101 in the ALLOHA heme trial for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, and CD45-targeted candidates TSC-102-A01 and TSC-102-A03 with cleared IND applications.
Recurring TCRX updates cover clinical data presentations, trial enrollment and manufacturing-process updates, FDA interactions, financial results, healthcare conference participation, and portfolio priorities. The company also describes early work in in vivo engineering for solid tumors and target discovery in T cell-mediated autoimmune disorders.
TScan Therapeutics (Nasdaq:TCRX), a clinical-stage biotech developing TCR-T cell therapies for cancer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026 at 11:30 a.m. ET.
A live webcast and 90-day replay will be available on TScan's investor relations website.
TScan Therapeutics (Nasdaq:TCRX) reported initial Cohort C data from the ALLOHA™ Phase 1 study of TSC-101 in heme malignancy patients undergoing allo-HCT. Of 19 enrolled patients, 17 had successful manufacturing and 14 received a first infusion; 11/14 achieved complete donor chimerism within ~3 weeks. Safety remained generally well-tolerated and consistent with prior experience. TScan remains on track to enroll the first patient in the pivotal ALLOHA-2™ Phase 3 study this month and is hosting a virtual KOL event on June 22, 2026.
TScan Therapeutics (Nasdaq:TCRX) and Cellares entered an agreement to evaluate automated clinical manufacturing of TSC-101, a TCR-T therapy candidate for patients with AML and MDS undergoing allo-HCT.
The collaboration uses Cellares’ Cell Shuttle and Cell Q platforms to assess a scalable, cost-efficient path to commercialization as TSC-101 advances toward a pivotal trial expected to begin in Q2 2026.
TScan Therapeutics (Nasdaq: TCRX) reported Q1 2026 results and a corporate update. Revenue was $1.0M; R&D expense $21.9M; G&A $8.2M; net loss $28.7M. Cash and cash equivalents were $128.1M, funding operations into the second half of 2027.
Clinical milestones: early Cohort C ALLOHA data expected Q2 2026; Phase 3 initiation of TSC-101 planned Q2 2026; Phase 1 starts for TSC-102-A01/A03 targeted for H2 2026; ASGCT poster on CD45 TCRs in May 2026.
TScan Therapeutics (Nasdaq: TCRX) will present a poster at the American Society of Gene and Cell Therapy 29th Annual Meeting, May 11–15, 2026 in Boston and virtually. The poster, Abstract ID 1256, covers CD45-targeted TCR-T therapies to address residual disease after allogeneic hematopoietic cell transplantation. The poster session is Tuesday, May 12 with a reception 5:00–6:30 p.m. ET in the Poster Hall at the Thomas M. Menino Convention & Exhibition Center. Presentation materials will be posted to the company’s Publications page at tscan.com after the event.
TScan Therapeutics (Nasdaq: TCRX) will present in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00 p.m. ET. A live webcast will stream at the company’s Events and Presentations page and an archived replay will be available for 90 days.
TScan Therapeutics (Nasdaq: TCRX) reported Q4 and full‑year 2025 results and a heme‑program update on March 4, 2026. Key items: IND clearances for TSC‑102‑A01 and TSC‑102‑A03, completion of Cohort C enrollment for ALLOHA™ using commercial manufacturing, and a cash runway into H2 2027.
Financials: Q4 revenue was $2.6M (Q4 2024: $0.7M); FY2025 revenue was $10.3M (FY2024: $2.8M). Pro forma shares including pre‑funded warrants totaled 129.9M as of Dec 31, 2025.
TScan Therapeutics (Nasdaq: TCRX) completed enrollment in Cohort C of its Phase 1 ALLOHA™ study, treating patients with a new commercial-ready manufacturing process and enrolling over ten patients. The company also received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 (HLA A*01:01 and A*03:01).
TScan plans to share Cohort C safety and early chimerism data in Q2 2026, launch a pivotal TSC-101 trial in Q2 2026, and initiate Phase 1 studies for both TSC-102 candidates in the second half of 2026.
TScan Therapeutics (Nasdaq: TCRX) will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 11:50 a.m. ET in Boston.
The hybrid presentation includes an analyst Q&A and a live webcast via the company’s Events and Presentations page, with an archived replay available for 90 days.
TScan Therapeutics (NASDAQ: TCRX) reported updated ALLOHA™ Phase 1 data for TSC-101 in heme malignancy patients undergoing allogeneic HCT presented at ASH on Dec 6, 2025. As of a Sept 19, 2025 cut, treatment-arm outcomes showed improved relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) versus control.
All 3 TSC-101 patients reaching two-year follow-up remained relapse-free versus 1 of 4 in control. No dose-limiting toxicities were observed. FDA agreed to a pivotal study design; pivotal start targeted Q2 2026. Manufacturing time reduced from 17 to 12 days.